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After an increase in the number of reported cases 
of Pneumocystis jirovecii pneumonia in England, we in-
vestigated data from 2000–2010 to verify the increase. 
We analyzed national databases for microbiological and 
clinical diagnoses of P. jirovecii pneumonia and associ-
ated deaths. We found that laboratory-confirmed cases in 
England had increased an average of 7% per year and 
that death certifications and hospital admissions also in-
creased. Hospital admissions indicated increased P. jir-
ovecii pneumonia diagnoses among patients not infected 
with HIV, particularly among those who had received a 
transplant or had a hematologic malignancy. A new risk 
was identified: preexisting lung disease. Infection rates 
among HIV-positive adults decreased. The results con-
firm that diagnoses of potentially preventable P. jirovecii 
pneumonia among persons outside the known risk group 
of persons with HIV infection have increased. This finding 
warrants further characterization of risk groups and a re-
view of P. jirovecii pneumonia prevention strategies.
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 Increasing Pneumocystis Pneumonia, England
Anecdotal reports from clinicians suggest that incidence of Pneumocystis jirovecii pneumonia, previously re-
ferred to as P. carinii pneumonia or PCP, among immuno-
suppressed patients, especially renal transplant recipients, 
has increased substantially (1). To investigate this claim, 
we analyzed data for January 2000 through December 
2010, using several national data sources: Hospital Episode 
Statistics, routine laboratory reporting, death certificate 
data, and HIV surveillance data. 
P. jirovecii pneumonia gained notoriety during the 
AIDS pandemic (2); however, the reservoirs, modes of 
transmission, and pathogenesis of this organism remain 
poorly understood (3). Subclinical infection is considered 
common because studies have shown that anti–P. jirovecii 
antibodies develop during early childhood (4). Reactivation 
of latent infection after immunosuppression of the host was 
thought to be the main pathogenic mechanism (3); how-
ever, recent studies indicate that person-to-person spread 
might cause acute infection in susceptible persons (5).
Although not fully characterized, the known risk fac-
tors for P. jirovecii infection include impaired immunity 
because of HIV infection, hematologic malignancies, and 
connective tissue disorders (6). Immunosuppressive agents 
used to treat or prevent graft rejection have been implicated; 
such agents include corticosteroids, methotrexate, cyclo-
sporine, mycophenolate mofetil, bendamustine, cyclophos-
phamide (7–11), and, recently, novel immunomodulating 
drugs, such as tumor necrosis factor–α inhibitors (12).
Prophylactically administered oral trimethoprim–sul-
famethoxazole, dapsone, or atovaquone prevent the clini-
cal manifestation of P. jirovecii infection. Also effective 
for decreasing P. jirovecii infection incidence among HIV-
positive patients with a CD4+ count <200/�L is routine pro-
phylactic administration of antimicrobial drugs (13,14).
Given the existence of effective chemoprophylaxis, 
identification of new risk groups might help prevent future 
increases in P. jirovecii infection incidence. Therefore, we 
conducted a retrospective analysis of multiple national data 
sources to examine trends in P. jirovecii infection. 
The Health Protection Agency has approval from the 
National Information Governance Board for Health and 
Social Care for the collation of surveillance data in ac-
cordance with section 251 of the National Health Service 
Act 2006. No additional ethical approval was required for 
this study.
Materials and Methods
Hospital Episode Statistics
The Hospital Episode Statistics (HES) database con-
tains details of all inpatient admissions to National Health 
Service hospitals in England. We identified all patients 
for whom an International Classification of Diseases,10th 
Revision (ICD-10), code B59, which corresponds with 
P. jirovecii infection, was recorded in any of the first 10 
diagnosis fields from January 2000 through December 
2010. By using ICD-10 and Operating Procedure Code 
Supplement 4 codes, we then subdivided cases into non–
mutually exclusive, condition-specific categories that 
are frequently cited in the literature in association with 
P. jirovecii (7–13,15–19). The categories covered were 
renal failure, hematologic malignancy, other hematologic 
disorders, systemic connective tissue disorders, inflam-
matory diseases (such as rheumatoid or psoriatic arthri-
tis), and receipt of immunosuppressive agents or an organ 
transplant. Patients with chronic lung conditions, such as 
pulmonary fibrosis, were categorized as a single group, 
given the observed frequency in this study of concurrence 
of this condition with P. jirovecii infection. Patients who 
did not fit into any risk category were also included in 
the analysis.
We cross-checked for duplicate records and selected 
the record of first admission for each patient. We examined 
information about sex, age, and geographic distribution of 
patients. HIV-infected patients were excluded from analy-
sis because the clinical records for these patients did not 
contain patient-identifiable information (unlike the other 
clinical records in the HES database), thereby making iden-
tification and exclusion of duplicate records not possible 
for this group.
Routine Laboratory Reporting
LabBase2 is the Health Protection Agency’s national 
communicable diseases database for England, Wales, and 
Northern Ireland; it receives semiautomated downloads 
of results from 99% of microbiology diagnostic laborato-
ries (Health Protection Agency, unpub. data). Laboratory-
confirmed cases of P. jirovecii infection in England during 
2000–2010 were extracted from LabBase2, and duplicate 
laboratory samples were excluded.
Death Certificate Data
For the study period, deaths in England with an ICD-
10 clinical code indicating P. jirovecii as the cause or con-
tributory cause of death were extracted from Office for 
National Statistics data. Deaths from P. jirovecii infection 
linked to a diagnosis of HIV or AIDS were also analyzed.
HIV Surveillance Data
Data from the Health Protection Agency’s HIV and 
AIDS New Diagnoses and Deaths database were analyzed 
(20). Because HIV surveillance data are available for adults 
only, epidemiologic information in this study was restrict-
ed to patients >15 years of age. P. jirovecii infections were 
reported as co-infections at the time of HIV diagnosis, as 
subsequent AIDS diagnoses, or as the cause of death.
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Statistical Analyses
We used the statistical software STATA/SE 11.2 (21) 
for all analyses. Poisson regression with an offset for resi-
dent population, which used Office for National Statistics 
midyear estimates, was used to calculate the annual inci-
dence rate ratio with 95% CIs. The Pearson χ2 test was used 
to examine changes in the proportion of cases by risk cat-
egory over time (2000–2005 vs. 2006–2010).
Results
The absolute numbers of cases of P. jirovecii pneu-
monia in England during 2000–2010, reported by each na-
tional surveillance system, are shown in Figure 1 and Table 
1. We describe data from each system separately.
Hospital Episode Statistics
During the study period, HES recorded 2,258 cases 
of P. jirovecii pneumonia. The number of cases increased 
from 157 in 2000 to 352 in 2010, an average annual in-
crease of 9% (p<0.001).
Cases reported to HES were not restricted to a par-
ticular geographic area, and the data showed no obvious 
seasonal trends. Because the increase in cases began in 
the latter half of the decade (Figure 1), we compared data 
from 2000–2005 with that from 2006–2010. This com-
parison showed a marked change in the age distribution 
of patients hospitalized for P. jirovecii infection during 
2006–2010; relatively more patients were 60–69 years of 
age (Figure 2). Among all age groups, there was a higher 
proportion of male than female patients with P. jirovecii 
infection.
During the study period, 81% of patients within the 
HES database who had a diagnosis of P. jirovecii pneumo-
nia could be classified according to a defined risk category 
(Table 2). Most (40.6%) had a hematologic malignancy, and 
17.5% had preexisting lung disease. Relative distribution 
of risk groups differed significantly between 2000–2005 
and 2006–2010 for all risk categories (χ2 28.2, 7 degrees 
of freedom, p<0.001). The numbers of patients with P. jir-
ovecii pneumonia increased significantly in all risk groups, 
but the difference in rates between the 2 periods was most 
marked among patients who had undergone transplantation, 
47% of whom had undergone kidney transplantation during 
2000–2010. The number of patients who were not in any of 
the risk groups described above dropped by 19% between 
the 2 periods. This test was conservative because there was 
some overlap between the risk categories.
Routine Laboratory Reporting
During the study period, LabBase2 recorded 765 
laboratory-confirmed cases. Reported cases of P. jirovecii 
pneumonia remained relatively unchanged during 2000–
2006 (range 41–77 cases/year, mean 55 cases/year) but 
increased from 76 cases in 2007 to 98–104 cases during 
2008–2010 (Figure 1), particularly in older patients. The 
male-to-female ratio of P. jirovecii pneumonia patients 
during 2000–2010 was 2.5 to 1.0.
Death Certificate Data
Deaths for which P. jirovecii pneumonia was recorded 
as a cause or contributing factor rose from 57 in 2001 to 
94 in 2010 (p<0.001). For several years, the numbers of P. 
jirovecii infections reported on death certificates as a con-
tributory cause of death were greater than those captured by 
laboratory reports (Figure 1).
HIV Surveillance Data
The numbers of patients with P. jirovecii pneumonia 
and HIV infection decreased 7% per year during 2000–
2010 (p<0.001) (Figure 3). Most P. jirovecii infection di-
agnoses were made at the time of HIV diagnosis. Within 
this group of HIV-infected patients, death from P. jirovecii 
infection remained relatively stable over this period.
Discussion
In this study, we found an increasing trend in rates for 
clinical cases recorded in HES and microbiologically con-
firmed and reported cases in England during 2000–2010. 
This finding suggests a real increase in the numbers of 
cases of P. jirovecii pneumonia diagnosed. We also found 
an association between P. jirovecii infection and a variety 
of chronic lung diseases not described in the literature as 
being associated with P. jirovecii infection. On the basis of 
these data, we propose preexisting lung disease as a new P. 
jirovecii pneumonia risk category.
The HES database yielded 2,258 cases of P. jirovecii 
pneumonia during 2000–2010, but LabBase2 found only 
765. The differences in number of cases suggests substan-
tial underreporting by laboratories, although most cases 
might be diagnosed on the basis of clinical or radiologic 
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Figure 1. Pneumocystis jirovecii infections reported by national data 
collection systems, England, UK, 2000–2010. Hospital admissions 
exclude patients with HIV diagnoses.
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findings or by immunofluorescence in the cytology depart-
ment without being microbiologically confirmed.
An analysis of the Health Protection Agency database 
of HIV-infected persons shows clear evidence of a substan-
tial reduction in P. jirovecii infections during 2000–2010, 
consistent with an earlier diagnosis of HIV and receipt of 
effective antiretroviral therapy (14). P. jirovecii infections 
among HIV-infected persons declined, whereas P. jirove-
cii infections among non–HIV-infected persons increased, 
suggesting that other risk factors must be responsible for 
the increased numbers of cases.
Given the substantial illness and death associated with 
P. jirovecii infection and the resources needed to manage 
these cases, the increase in cases is of serious concern. 
Many patients need treatment in intensive care units. How-
ever, prophylactic use of antimicrobial drugs is highly ef-
fective for preventing the disease. A study in the United 
States suggested that almost $5 million a year could be 
saved in the state of Maryland alone if prophylaxis were 
instituted for all HIV-positive patients at risk for P. jirove-
cii infection (22).
Potential Causes of the Observed Increase 
The increased number of cases might reflect changes 
in ascertainment of cases and increased infections in immu-
nosuppressed patients who have received chemotherapy. 
It is possible that ascertainment increased over the study 
period because of improved diagnostic methods; immuno-
fluorescence staining is being replaced by more sensitive 
PCR methods (23). We were not able to test the hypothesis 
that the increased number of cases is the result of increased 
testing for P. jirovecii because the laboratory surveillance 
system captures positive samples only, not the total number 
of samples submitted. However, the change in age distribu-
tion of patients toward a much older age group suggests 
that increased testing is not the main reason for increased 
case detection.
With regard to immunosuppression, an area that has 
seen an increase in the use of potent immunosuppressant 
agents is transplant surgery. Recipients who are not well 
matched to donor human leukocyte antigens now receive 
more powerful drugs. That said, the proportion of patients 
receiving renal transplants with a moderate degree of hu-
man leukocyte antigen mismatch has remained stable, 
represented by 43.9% of patients during financial year 
2009–10 (National Health Service Blood and Transplant 
Authority, pers. comm.). Similarly, data from the National 
Health Service Blood and Transplant Authority indicate 
that the number of renal transplantations increased by 25% 
during 2006–2010. Again, this increase was not propor-
tional to that observed for P. jirovecii infections reported 
for renal transplant recipients, which was ≈388% over the 
same period (National Health Service Blood and Trans-
plant Authority, pers. comm.), so the increase cannot be 
explained simply by an increase in the number of patients 
in this risk group.
The largest group of persons affected by P. jirovecii 
pneumonia is those with hematologic malignancies. This 
finding might reflect the 30% increase in diagnoses of 
these malignancies during 2000–2010 (24). However, the 
increase in patients in this risk group with P. jirovecii pneu-
monia was 209% over the same period.
A possible explanation for the increase in P. jirovecii 
pneumonia cases is an increase in the number of poten-
tially vulnerable patients who did not receive appropriate 
prophylactic therapy. Guidelines recommend the use of 
antimicrobial drug prophylaxis for kidney transplant re-
cipients and for patients with hematologic malignancies 
who are receiving certain chemotherapy (25–28). A Co-
chrane review recommends prophylaxis for patients with 
hematologic malignancies and for recipients of bone mar-
row and solid organ transplants (29). Our study identified a 
new group at risk for P. jirovecii infection: patients with 
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Table 1. Annual change in incidence rate of Pneumocystis jirovecii cases, England, UK, 2000–2010* 
Surveillance system Total no. cases Annual incidence rate ratio (95% CI)† 
Laboratory reporting 765 1.07 (1.05–1.09) 
Hospital admissions‡ 2,258 1.09 (1.08–1.11) 
HIV surveillance data 779 0.94 (0.92–0.96) 
Death registrations 722 1.04 (1.01–1.06) 
*Midyear population estimates used.  
†p<0.001 for all. 
‡Excludes P. jirovecii diagnoses for patients with diagnosed HIV infection. 
Figure 2. Age and sex distribution of patients with Pneumocystis 
jirovecii infections (excluding HIV-infected patients) among hospital 
admissions, England, UK, 2000–2010.
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preexisting lung disease. To determine whether any preventa-
tive measures would be advisable for these patients will require 
further detailed characterization and quantification of risk 
within this group.
Another possible explanation for the increase in P. 
jirovecii pneumonia cases is increased transmission of the 
P. jirovecii organism between susceptible persons. Levels 
of exposure of susceptible persons to infectious persons 
might be increased as a result of changes in the delivery 
of health care. New, more transmissible strains could be 
emerging and leading to increased spread in the health care 
environment. Further investigation into the contribution of 
outbreaks—and, thus, increased person-to-person trans-
mission—to the increase is warranted.
As a result of increased awareness of P. jirovecii infec-
tion, other infections might be clinically misdiagnosed as 
P. jirovecii infection. In the HES database, some patients 
might have been incorrectly coded as having P. jirovecii 
pneumonia, thereby resulting in a misclassification bias, 
but we have no reason to suspect that this coding would 
have changed over time. The death statistics should also 
be interpreted with caution because the cause of death and 
contributory causes are probably not recorded consistently. 
The analyses did not differentiate between outbreaks and 
sporadic cases of disease because this information could 
not be reliably determined from the data sources used. Al-
though the most recent data might be subject to reporting 
delays, such delays would result in underestimation rather 
than overestimation of recent cases.
Next Steps
Incidence of P. jirovecii pneumonia has increased 
across all groups of immunosuppressed patients known to 
be at risk for this infection (excluding HIV patients) and 
in new groups not previously known to be at risk. To de-
termine whether current indications for prophylaxis need 
to be widened, enhanced surveillance should be introduced 
to help characterize any additional groups of patients for 
whom prophylaxis is not currently recommended but who 
might be at risk. Particular focus should be given to pa-
tients with chronic lung disease, systemic inflammatory 
diseases, and solid tumors and to transplant recipients who 
do not currently fulfill the criteria for prophylaxis. When 
introducing new immunosuppressive agents and regimens, 
consideration should be given as to whether these agents 
might increase the patients’ risk for P. jirovecii pneumonia.
More studies involving sequencing of P. jirovecii clini-
cal isolates identified by PCR, coupled with national sur-
veillance, should be used to better understand transmission 
dynamics and thereby inform infection control policies and 
clarify the role of any environmental factors (1,30–32). More 
basic knowledge of the biology, pathogenesis, virulence fac-
tors, and the contribution of different strains will be crucial 
for explaining observed changes in P. jirovecii epidemiology.
To ensure adherence to current guidelines and to en-
sure that preventive prophylaxis is optimal for all groups at 
risk for this potentially life-threatening infection, auditing 
of prescribing practices for patients known to be at risk is 
warranted. Raising awareness among clinicians could also 
help ensure that prophylaxis is correctly used.
In conclusion, data from a variety of national sources 
demonstrate an increase in the number of cases of P. jir-
ovecii in non–HIV-infected persons. P. jirovecii infections 
are largely preventable by use of inexpensive drugs. The 
current case numbers are taking a substantial toll on health 
care costs and human health. Further investigation leading 
to improved preventive strategies for this largely prevent-
able infection is warranted.
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Table 2. Proportion of all Pneumocystis jirovecii–associated hospital admissions and change in population rates over time, England, 
UK, 2000–2010 
Risk category* 
No. admissions (% all cases) 
 
Annual rate/million population Rate ratio between 
periods (95% CI) 2000–2005 2006–2010 2000–2005 2006–2010 
Any transplant† 59 (6.3) 193 (14.7)  0.20 0.75 3.80 (2.84–5.09) 
Other lung disease‡ 120 (12.8) 276 (21.0)  0.24 0.47 1.97 (1.47–2.64) 
Hematologic disorders 217 (23.1) 354 (26.9)  0.32 0.81 2.55 (2.00–3.25) 
Hematologic malignancy 349 (37.1) 568 (43.1)  1.17 2.21 1.89 (1.66–2.16) 
Connective tissue/inflammatory disease§ 71 (7.6) 120 (9.1)  0.31 0.62 2.02 (1.56–2.61) 
Renal failure and dialysis 95 (10.1) 208 (15.8)  0.16 0.35 2.23 (1.56–3.17) 
Immunosuppressive/ chemotherapeutic 
drugs 
47 (5.0) 90 (6.8)  0.73 1.38 1.90 (1.60–2.25) 
Malignancy other than hematologic 92 (9.8) 160 (12.2)  0.40 1.07 2.67 (2.16–3.31) 
Not in the above risk categories 255 (27.1) 177 (13.4)  0.85 0.69 0.81 (0.67–0.98) 
Total no. cases¶ 941 1,317  3.15 5.13 1.62 (1.50–1.77) 
*Excludes HIV infection. 
†includes liver, heart, lung, kidney and bone transplants. 
‡Includes tuberculosis, chronic obstructive pulmonary disease, cystic fibrosis, bronchiectasis, asthma, and interstitial lung disease. 
§Includes systemic connective tissue disorder, psoriatic arthropathy, rheumatoid arthritis, and inflammatory bowel disease. 
¶Because some patients belong to >1 risk category, numbers do not add up to the total number of cases. 
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From the Greek leptos (slender) and speira (coil), a genus of bacteria consisting of single, finely coiled, 
motile, aerobic cells. In 1886, German physician Adolf 
Weil described a clinical syndrome characterized by 
splenomegaly, jaundice, and nephritis, although the disease 
was likely recognized in ancient China as an occupational 
hazard of rice farming. The organism was first described 
in 1907 by Arthur Stimson, who observed spirochetes with 
curved ends in the kidneys of a patient thought to have 
died of yellow fever. He named it Spirochaeta interrogans 
because it looked like a question mark.
The cause of Weil’s disease was isolated independently 
in 1915 in Japan and Germany. In Japan, Inada et al. 
detected spirochetes, which they named Spirochaeta 
icterohaemorrhagiae, in the blood of coal miners with infectious 
jaundice. In Germany, 2 groups of physicians (Uhlenhuth et 
al. and Hubener et al.) studied soldiers afflicted with “French 
disease” in the trenches of northeastern France. The Germans 
were arguing over priority, however, and overlooked the 
publications by Inada’s group, which predated their own by 
8 months. The genus Leptospira was suggested in 1917 by 
Hideyo Noguchi “on account of its fine and minute windings.”
